Verinetics is a brand that offers better control for controlled substances, specifically targeting the issue of Opioid Use Disorder (OUD) in the United States. With over 2 million Americans affected by OUD, the overprescribing of opioids has resulted in widespread misuse, leading to negative health and economic consequences. Verinetics aims to address this problem by providing solutions for two main challenges.

Firstly, they strive to reduce the number of new cases of OUD, emphasizing prevention as a key component. Secondly, they focus on improving treatment for the 2+ million Americans already suffering from OUD, offering better options for their recovery. One significant gap Verinetics has identified is the underdiagnosis of individuals dependent on opioids who are receiving high morphine equivalent prescriptions.

Limited access to medically proven treatments is another contributing factor. To bridge this gap, Verinetics aims to increase methadone take-home doses for a specific patient population that has found benefit from this therapy. By addressing barriers such as social stigma, limited clinic hours, and financial constraints, Verinetics aims to provide more accessible and comprehensive treatment options for OUD.

Their mission-driven approach is backed by a dedicated management team and has garnered attention from investors. If you are compelled by their mission, visit their investor page to learn more or contact them through their provider portal